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Several traits associated with asthma phenotypes, such as high total serum immunoglobulin E and bronchial
hyperresponsiveness, have been linked by numerous genome-screen studies and linkage analyses to markers on
human chromosome 5q31-q34. In the present article, we describe UGRP1 (encoding uteroglobin-related protein
1) as one of asthma-susceptibility genes that is located on chromosome 5q31-q32. UGRP1 is a homodimeric secretory
protein of 17 kDa and is expressed only in lung and trachea. The GrA polymorphism was identified at5112 bp
in the human UGRP1 gene promoter. The5112A allele is responsible for a 24% reduction in the promoter activity
in relation to the5112G allele, as examined by transfection analysis. Electrophoretic mobility-shift analysis revealed
that an unknown nuclear factor binds to the region around 5112 bp. The binding affinity with the 5112A
oligonucleotide was reduced by approximately one half, as compared with the 5112G oligonucleotide. In a case-
control study using 169 Japanese individuals (84 patients with asthma and 85 healthy control individuals), those
with a 5112A allele (G/A or A/A) were 4.1 times more likely to have asthma than were those with the wild-type
allele (G/G).
Introduction
Bronchial asthma is a complex, inheritable inflamma-
tory disorder of the airways, characterized by reversible
airflow obstruction, airway inflammation, and bron-
chial hyperresponsiveness (BHR) (McFadden and Gil-
bert 1992). A number of genetic studies have identified
several chromosomal regions that contribute to the de-
velopment of asthma and asthma-associated pheno-
types such as BHR and atopy (Postma et al. 1995; The
Collaborative Study on the Genetics of Asthma 1997;
Ruffilli and Bonini 1997; Bleecker 1998; Cookson and
Moffatt 2000; Ober and Moffatt 2000). Among these
regions are human chromosomes 5q31-q34, 6p21-p23,
11q13, 12q15-q24, 14q12, and 16p12. Chromosome
5q31-q34 contains numerous gene candidates that po-
tentially may play a role in the airway inflammation
associated with atopic asthma, including a number of
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proinflammatory cytokines such as interleukin (IL)-3,
-4, -5, -9, and -13, granulocyte macrophage colony-
stimulating factor (CSF), and the b2-adrenergic receptor
(ADRB2) (Postma et al. 1995; Ruffilli and Bonini 1997;
Bleecker 1998; Cookson and Moffatt 2000; Ober and
Moffatt 2000).
Our previous study on the mouse uteroglobin-related
protein 1 (Ugrp 1) gene and its encoded protein (Niimi
et al. 2001) suggested that the human UGRP1 gene
(MIM 606531) is a plausible asthma candidate gene,
for the following reasons: First, the mouse Ugrp1 gene
is located on chromosome 18C-D, a region that is syn-
tenic with human chromosome 5q31-q34, which has
been assigned as one of the asthma-susceptibility gene
loci (Niimi et al. 2001). Second, UGRP1 exhibits an
amino acid sequence similar to that of Clara cell secre-
tory protein (CCSP/CC16) (Niimi et al. 2001), which
is thought to function as an anti-inflammatory agent by
inhibiting chemotaxis and phagocytosis of monocytes
and neutrophils and which modulates production and/
or activity of various mediators of the inflammatory
response, including phospholipase A2 (PLA2), inter-
feron-g, and tumor-necrosis factor a (Broeckaert and
Bernard 2000; Mukherjee and Chilton 2000). Third,
UGRP1 is mainly expressed in pulmonary airways, and
a high level of expression was found in the epithelial
cells of the trachea, bronchus, and bronchioles (Niimi
et al. 2001). Lastly, the level ofUgrp1mRNA decreased
in the lungs of the antigen-induced inflammation model
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mouse (Niimi et al. 2001), in a way similar to that
observed for CCSP/CC16; CCSP/CC16 protein expres-
sion was decreased in humans with asthma (Shijubo et
al. 1999) and after induction of airway inflammation
in humans (Lensmar et al. 2000) and animals (Arsalane
et al. 2000; Hayashida et al. 2000).
UGRP1 is a homodimeric secretory protein of un-
known function (Niimi et al. 2001). The mouse and hu-
man UGRP1 cDNAs encode a protein of 91 and 93
amino acids, respectively, of which the N-terminal 21
amino acid residues exhibit a characteristic signal se-
quence that may function to target the protein to a se-
cretory pathway (Niimi et al. 2001). The mouse Ugrp1
gene is ∼2.9 kb in length and is composed of three exons
(Niimi et al. 2001). Homologous UGRP2 genes have
been identified in both mouse and human and, together
with the mouse and human UGRP1 genes, constitute a
new gene family (Niimi et al. 2001). The human UGRP1,
human UGRP2, and mouse UGRP2 share 81%, 41%,
and 33% amino acid sequence identity, respectively, with
mouse UGRP1 (Niimi et al. 2001).
Mutation screening of asthma candidate genes aims
to detect sequence variations that alter the concentra-
tion or activity of the protein that is coded by that gene
and that ultimately contributes to the development of
clinical asthma. To this end, the human UGRP1 gene
was isolated and characterized. Screening for sequence
variations in the exons and the 5′ promoter region of
the gene among patients with asthma and healthy con-
trol individuals revealed the presence of a point muta-
tion, in the promoter region, that appears to be re-
sponsible for reduced transcriptional activity of the gene
and is associated with an increased risk of asthma.
Material and Methods
Cloning and DNA Sequencing
A human UGRP1 genomic DNA was isolated from
a human BAC DNA library (Incyte Genomics) and Hu-
man GenomeWalker kit (Clontech). The genomic DNA
fragments were sequenced using an ABI Prism Dye Ter-
minator Cycle Sequencing Ready Reaction Kit and a
model 377 DNA sequencer (PE Applied Biosystems).
The transcription start site of the human UGRP1 tran-
script was determined by a SMART RACE cDNA am-
plification kit (Clontech), using 2 mg of human adult
lung total RNA. DNA sequence analyses indicated the
presence of multiple transcription start sites. Since the
majority of clones (12/16) had exactly the same se-
quence, we refer to this site as the major transcription
start site.
Chromosomal Mapping
A human UGRP1 probe of an entire BAC genomic
clone labeled with biotin or digoxigenin was used for
FISH of chromosomes derived from methotrexate-syn-
chronized normal peripheral lymphocytes. Conditions of
hybridization; detection of hybridization signals; digital-
image acquisition, processing, and analysis; and direct
fluorescent signal localization on banded chromosomes
were performed as described elsewhere (Zimonjic et al.
1995).
Genotyping
Genomic DNA was extracted from peripheral leu-
kocytes isolated from EDTA-anticoagulated blood
through use of a commercially available DNA isolation
kit (DnaQuick; Dainippon Pharmaceutical). Genotyp-
ing for the 112G/A polymorphism was performed
using a PCR fragment amplified by the primers 5′-CCT-
CCAGATTGCTTTCACAACTGGG-3′ and 5′-CAAA-
GTGTGATGGCTGCTTTTGCAC-3′. PCR was per-
formed, in a 20-ml reaction mixture containing 50 ng
of genomic DNA, under the following conditions: de-
naturation at 94C for 30 s and annealing and exten-
sion at 68C for 1 min, for 35 cycles. Amplified DNA
fragments were purified and sequenced.
Transfection and Reporter-Gene Assays
A 294-bp fragment (from209 to85) of the human
UGRP1 gene promoter was prepared by PCR, using two
forms (112G/G and 112A/A) of genomic DNA as a
template, each of which was separately subcloned into
an NheI-XhoI site of the pGL3-Basic luciferase reporter
vector (Promega) to generate the pGL3112G and
pGL3112A plasmids.
Conditions used for the culturing of human lung ad-
enocarcinoma NCI-H441 cells, as well as the method of
transfection, are described elsewhere (Niimi et al. 2001).
Luciferase activity was normalized to b-galactosidase ac-
tivity, and the relative luciferase activity of the reporter
constructs was expressed in relation to the activity of
the pGL3-Basic plasmid, which was assigned a value of
1. Data are the mean values of four independent ex-
periments, plus or minus the SD.
Electrophoretic Mobility–Shift Assays (EMSAs)
Single-stranded oligonucleotides were annealed to
produce double-stranded DNA having either G or A at
112 bp (112G or 112A oligonucleotide). Double-
stranded DNA was end-labeled with a-[32P]dCTP and a
DNA polymerase Klenow fragment (Life Technologies).
Nuclear extracts were prepared from human lung NCI-
H441 cells, and EMSA was performed as described else-
where (Niimi et al. 2001). An oligonucleotide containing
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Figure 1 Human UGRP1 gene structure. The structure of the gene and the sequences at the exon-intron boundaries are shown in uppercase
(exon) and lowercase (intron) letters. Splicing donor and acceptor consensus sequences are shown in boldface.
Figure 2 UGRP1 expression. Human multiple tissue expression
array was hybridized with 32P-labeled human UGRP1 cDNA probe.
RNA sources are as follows: A1 p whole brain; A2 p amygdala; A3
p caudate nucleus; A4 p cerebellum; A5 p cerebral cortex; A6 p
frontal lobe; A7 p hippocampus; A8p medulla oblongata; B1p oc-
cipital lobe; B2 p putamen; B3 p substantia nigra; B4 p temporal
lobe; B5p thalamus; B6p subthalamic nucleus; B7p spinal cord; C1
p heart; C2p aorta; C3p skeletal muscle; C4p colon; C5p bladder;
C6p uterus; C7p prostate; C8p stomach; D1p testis; D2p ovary;
D3 p pancreas; D4 p pituitary gland; D5 p adrenal gland; D6 p
thyroid gland; D7 p salivary gland; D8 p mammary gland; E1 p
kidney; E2 p liver; E3 p small intestine; E4p spleen; E5p thymus;
E6p peripheral leukocyte; E7p lymph node; E8p bone marrow; F1
p appendix; F2 p lung; F3 p trachea; F4 p placenta; G1 p fetal
brain; G2 p fetal heart; G3 p fetal kidney; G4 p fetal liver; G5 p
fetal spleen; G6 p fetal thymus; and G7 p fetal lung.
a CCAAT/enhancer binding protein (C/EBP) a/b con-
sensus binding sequence (TTGCGCAAT) (Ryden and
Beemon 1989) was from the C/EBP Gelshift kit (Geneka
Biotechnology).
Subjects for the Case-Control Study
Initial screening for a possible variation of theUGRP1
gene sequence was performed using 51 subjects (26
males and 25 females) from various ethnic backgrounds,
with and without asthma/allergy (rhinitis), who were
volunteers living in the local Philadelphia area. For a
case-control study, a total of 84 Japanese patients (40
males and 44 females) with bronchial asthma were re-
cruited from the pulmonary clinic at the Hokkaido Uni-
versity Hospital, Sapporo, Japan, between 1990 and
1992. Asthma was diagnosed by the following three cri-
teria: (1) presence of at least two symptoms (recurrent
cough, wheezing, or dyspnea), (2) presence of reversible
airflow limitation (15% variability in forced expiratory
volume per second or in peak expiratory flow rate, either
spontaneously or with an inhaled short-acting b2-ago-
nist) or airway hyperresponsiveness to methacholine,
and (3) absence of other pulmonary diseases, such as
chronic obstructive pulmonary disease. Antigen-specific
immunoglobulin E (IgE) was examined for 10 common
inhaled antigens, including house-dust mite, molds, pol-
lens, and animal dander (cat and dog). Of 84 patients,
57 (67.9%) were positive for at least one of these
antigens.
Eighty-five subjects were frequency matched by age
and were selected from among healthy Japanese vol-
unteers without history of bronchial asthma or other
respiratory symptoms. For both patients with asthma
and healthy control individuals, information about life-
style, such as cigarette smoking, was obtained by stan-
dardized interview by a physician. The study was ap-
proved by the University Ethics Committee. Informed
consent was obtained from all participants, according
to the Helsinki Declaration.
Statistical Analyses
Frequencies of the 112A allele and of the G/A or A/
A genotype were compared between patients with asthma
and healthy control individuals, by the use of x2 test. The
mean age and IgE level were continuous variables and
were compared between cases and controls by the non-
parametric Kruskal-Wallis test. Smoking status was di-
chotomized as current smokers versus ex-/nonsmokers.
The odds ratio (OR) and 95% confidence interval (CI)
for the association of asthma diagnosis with the UGRP1
genotype were estimated by logistic regression (Breslow
and Day 1980).
Results
Characterization of the Human UGRP1 Gene
The human UGRP1 gene is 2,900 bp in length and
consists of three exons; the structure resembles the or-
thologous mouse Ugrp1 gene (fig. 1) (Niimi et al. 2001).
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Figure 3 FISH chromosomal localization of the humanUGRP1
gene. Chromosome 5 exhibits symmetrical fluorescent signals of the
UGRP1 gene at region 5q31-q32, as depicted by enhanced DAPI-
induced chromosome banding.
All the exon-intron boundaries demonstrated a consen-
sus sequence for RNA splicing. Analysis of human
UGRP1 mRNA through use of a human multiple tissue
expression array (Clontech) revealed that it was only
expressed in lung and trachea; fetal lung had the highest
expression (fetal trachea was not tested), whereas, in
adults, higher expression was found in trachea, as com-
pared with very low expression in lung (fig. 2).
Chromosomal Localization of the Human
UGRP1 Gene
The human UGRP1 gene was mapped by FISH, on
chromosomes prepared from normal human peripheral
leukocytes (fig. 3). A symmetrical fluorescent signal on
sister chromatids was observed only on chromosome 5
at identical sites in 38 of 40 metaphases recorded from
two separate experiments. In 20 metaphases analyzed
by imaging of 4′,6-diamidino-2-phenylindole (DAPI) G-
like banding, the FISH signal was localized on chro-
mosome 5 at region q31-q32, the region syntenic with
mouse chromosome 18C-D (Searle et al. 1989; DeBry
and Seldin 1996), to which the mouse Ugrp1 gene has
been assigned (Niimi et al. 2001). To confirm the identity
of chromosomes with specific signals, metaphases were
rehybridized with a human chromosome-painting probe
for chromosome 5. All metaphases with a specific signal
were painted with this probe (data not shown).
Polymorphism in the Human UGRP1 Gene Promoter
On the basis of our hypothesis that human UGRP1
may assume a role in asthma, an effort was focused on
detecting possible sequence variations in the human
UGRP1 gene that alter the concentration or activity of
the coded protein, ultimately contributing to the devel-
opment of clinical asthma. Initially, DNAs from 51 ran-
domly selected individuals with or without asthma/allergy
(rhinitis) were screened for possible sequence variation(s)
in the coding region and in all the exon-intronboundaries.
No variations were found. A 585-bp upstream region
(GenBank accession number AF411473) of the gene was
then screened using the same DNA samples. The GrA
substitution was found at the 112-bp position, relative
to the transcription start site of the gene (fig. 4A). Of the
51 samples, 2 were homozygous and 9 were heterozygous
for the A allele.
The 112GrA Polymorphism Modulates the
Transcription of the UGRP1 Gene
To examine whether the 112GrA polymorphism
influences promoter activity of the UGRP1 gene, the
promoter sequence, connected to a luciferase reporter
gene, was transfected into human lung adenocarcinoma
NCI-H441 cells. The reporter activities were compared
between two constructs containing either G or A at
112 bp in the UGRP1 gene promoter region (fig. 4B).
Significantly lower luciferase reporter activity was de-
tected for the 112A construct, as compared with the
112G construct (24% decrease; ). These resultsP ! .01
suggest that the 112A allele may be associated with
the decreased transcriptional activity of theUGRP1 gene
in lungs.
Computer analysis was performed using TF (tran-
scription factor) Search (Heinemeyer et al. 1998), in an
attempt to identify a nuclear protein that binds to the
sequence around 112 bp and contributes to the tran-
scriptional activation of the human UGRP1 gene. The
C/EBP consensus sequence (T[G/T]TGG[A/T]NA) was
identified as a candidate transcription factor. The C/
EBPa/b consensus binding sequence (TTGCGCAAT)
(Ryden and Beemon 1989), when used as a competitor,
however, did not compete with the 112G oligonucleo-
tide for a specific DNA-protein complex formation (data
not shown), suggesting that the nuclear protein binding
to the sequence around 112 bp may not be a member
of the C/EBP family. It appears that an unknown nuclear
protein binds to a sequence similar to the C/EBP binding
site located around112 bp in the humanUGRP1 gene
promoter and activates transcription of the gene.
Allele-Specific Binding of a Nuclear Protein to
the 112GrA Polymorphic Site
Electrophoretic mobility shift analysis was then per-
formed, to examine whether the GrA nucleotide sub-
stitution at112 bp affects interaction of a nuclear pro-
tein(s) with the sequence around 112 bp, through use
of NCI-H441 cell nuclear extracts and 24-bp double-
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Figure 4 Human UGRP1 gene promoter analysis and the 112G/A polymorphism. A, Sequence of the promoter region used for trans-
fection analysis. Numbers indicate nucleotide positions relative to the major transcription start site, marked by a bent arrow (1). The nucleotide
112 is a polymorphic site, marked by an asterisk (*); the polymorphic G/A nucleotide is shown in boldface. The TATA box is boxed, and
the ATG initiation codon is shown in boldface. B, Reporter-gene assays of humanUGRP1 gene promoter constructs. Relative luciferase activities
of constructs harboring the human UGRP1 gene sequence from 209 to 85 bp, with either G (112G) or A (112A) at 112 bp, were
compared in transient transfection studies using NCI-H441 cells. Luciferase activities are shown; values are based on the activity obtained with
the pGL3-Basic vector (GL3) as 1. The constructs were tested in duplicate in four independent experiments. Values are mean  SD.
stranded oligonucleotide probes that had a sequence
from 123 to 100 bp of the UGRP1 gene promoter,
with either G or A at 112 bp (fig. 5A). A single band
due to a specific DNA-protein interaction was obtained
at the same mobility for both oligonucleotide probes
(data not shown). To determine whether this particular
nuclear protein binds preferentially to one of the oli-
gonucleotides, a series of competition assays was per-
formed, where a radiolabeled 112G probe competed
against an unlabeled 112G or 112A oligonucleotide
(fig. 5B and C). The unlabeled 112G oligonucleotide
was a more efficient competitor, having an approxi-
mately twofold-higher affinity for a specific DNA-pro-
tein complex formation, as compared with that of the
112A oligonucleotide. These results indicate that the
A residue at 112 bp lowers the binding affinity, albeit
not completely, of a particular nuclear protein to the site
around 112 bp. Thus, the GrA point mutation at
112 bp in the humanUGRP1 gene promoter decreases
the affinity of a particular nuclear protein to the binding
site around 112 bp, resulting in reduced transcrip-
tional activity and ultimately leading to a lower expres-
sion of the UGRP1 protein.
The 112A Allele Is Associated with an Increased Risk
of Asthma
A case-control study was then performed, to examine
whether the presence of the 112A allele is associated
with an increased risk of asthma. This analysis included
a total of 169 Japanese (98 males and 71 females); 84
patients with clinical diagnoses of asthma (case subjects)
and 85 without asthma (healthy control subjects). The
mean age of the 169 subjects was 45.6 years (range
18–81 years) and was similar between case subjects and
healthy control subjects (46.3 vs. 44.8 years; ).Pp .70
The mean IgE level was significantly higher among case
subjects than among control subjects (679.4 IU/ml vs.
140.4 IU/ml; ). The IgE level, however, didPp .0001
not differ by sex (443.4 IU/ml in men and 356.0 IU/ml
in women; ). The prevalence of smoking wasPp .69
lower in case subjects as compared with control subjects
(21% vs. 43%; ) but was similar between thePp .04
sexes (32% in men and 31% in women; ). ThePp .90
allele frequency of the 112A variant in the UGRP1
gene among case subjects was 22.0%, compared with
10% among healthy control subjects ( ) (tablePp .003
1). The prevalence of the A variant (G/A and A/A ge-
notype combined) was 40.5% (34 of 84) among case
subjects, compared with 17.6% (15 of 85) among con-
trol subjects ( ). With adjustment for IgE level,Pp .001
smoking status, age, and sex, a person with G/A or A/
A genotype was 4.1 times more likely to be asthmatic,
compared with those with G/G genotype. In addition,
every 100-IU/ml increase in IgE level increased the risk
of asthma 1.9-fold, on average (table 2). The correlation
between serum IgE level and the clinical expression of
allergy and asthma has been established (Burrows et al.
1989; Sears et al. 1991; Postma et al. 1995; Ruffilli and
Bonini 1997).
Discussion
We investigated the hypothesis that human UGRP1 plays
a role in asthma, by screening patients with asthma and
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Figure 5 Electrophoretic mobility shift analysis of the 112G/A polymorphic site. A, Oligonucleotide sequences containing G (112G)
or A (112A) at 112 bp (boldface), which were used as a probe or a competitor, are shown. The consensus sequence for C/EBP obtained
by Transcription Factor Search (Heinemeyer et al. 1998) is underlined. B, A specific DNA-protein complex, formed between a nuclear protein
in NCI-H441 cells and a 32P-labeled 112G fragment, was subjected to competition analysis in the presence of increasing concentrations (one
to ninefold) of unlabeled 112G or 112A oligonucleotide, as a competitor. A representative result is shown. C, Graphic demonstration of
the results obtained in B. ---------- p 112A oligonucleotide; ———— p 112G oligonucleotide. Band intensity was quantitated using
a PhosphoImager and ImageQuant program (Molecular Dynamics). Each value represents the mean of three independent experiments  SD.
Table 1
Frequency of 5112A Allele in the UGRP1 Gene among 169 Japanese Subjects with and without Asthma
SAMPLE
NO. OF INDIVIDUALS WITH GENOTYPE
FREQUENCY OF THE A ALLELE
(%)112G/G 112G/A 112A/A
Patients with asthma ( )np 84 50 31 3 22.0
Healthy control individuals ( )np 85 70 13 2 10.0
healthy control subjects for a possible sequence varia-
tion(s)—in exons, exon-intron boundaries, and pro-
moter sequences of the UGRP1 gene—that alters the
concentration or activity of the coded protein. The GrA
substitution was found at position 112 bp relative to
the transcription start site of the gene. Transfection and
EMSA analyses demonstrated that the GrA point mu-
tation at 112 bp in the human UGRP1 gene promoter
decreases affinity of a particular nuclear protein to the
binding site around 112 bp, resulting in reduced tran-
scriptional activity and ultimately leading to a lower
expression of UGRP1 protein. In a case-control study,
subjects with asthma had a significantly higher A allele
frequency, compared with healthy control subjects, sug-
gesting the importance of the A allele in development of
asthma.
UGRP1 is similar to CCSP/CC16, in its amino acid
sequence (25% identity in mouse) and site of tissue-
specific expression (Niimi et al. 2001). Both are secre-
tory proteins and exhibit decreased expression in in-
flamed mouse lungs (Arsalane et al. 2000; Hayashida
et al. 2000; Niimi et al. 2001). CCSP/CC16 is believed
to function as an anti-inflammatory agent, on the basis
of numerous in vivo and in vitro studies (Broeckaert
and Bernard 2000;Mukherjee and Chilton 2000). Thus,
decreased CCSP/CC16 expression has been found in
humans with asthma (Shijubo et al. 1999) and after
induction of airway inflammation in those with asth-
ma (Lensmar et al. 2000). The CCSP/CC16 knockout
mouse exhibited an increased level of inflammation, in-
flammatory cytokine production, and neutrophil infil-
tration in the lungs after infection with a virus or bac-
teria (Harrod et al. 1998; Hayashida et al. 2000).
Although the exact function of UGRP1 is not known,
it is possible that it may play a role as an anti-inflam-
matory agent, like CCSP/CC16, in the modulation of
pulmonary inflammation. In this regard, it is interesting
to note that the association of the 112A polymor-
phism with asthma appears to be independent of the
increase in IgE level. Furthermore, theUGRP1 genewas
mapped in the area where many proinflammatory cy-
tokine genes are located, including IL-3, -4, -5, -9, and
-13, as well as genes encoding granulocyte macrophage
CSF–2 and the receptor for CSF–1 (Postma et al. 1995;
The Collaborative Study on the Genetics of Asthma
1997; Ruffilli and Bonini 1997; Bleecker 1998; Cookson
and Moffatt 2000; Ober and Moffatt 2000).
The GrA polymorphism was recently reported at the
38-bp position of the CCSP/CC16 gene, located within
the exon 1 noncoding region that exhibits association
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Table 2
The Association of Asthma with UGRP1 Variant
and IgE Level
Variable OR (95% CI)a
G/A or A/A genotype 4.11 (1.51–11.17)
IgE 1.90 (1.41–2.58)
NOTE.—Logistic-regression models include both
variables shown and are adjusted for age, sex, and
smoking status. Age and IgE level were continuous var-
iables. Smoking status was either current or ex-/non-
smoker. The reference group for the UGRP1 genotype
is the wild type (G/G).
a The OR for the G/A or A/A genotype indicates
that persons who have either of these genotypes are
four times more likely to have asthma; the OR for
IgE indicates that every increase of 100 IU/ml in IgE
level elevates the risk of asthma 1.9-fold.
with an increased risk of asthma (Laing et al. 1998,
2000). The CCSP/CC16 gene is one of the asthma-sus-
ceptibility gene candidates located on chromosome
11q13 (Ruffilli and Bonini 1997; Ober and Moffatt
2000). In a case-control study, the frequency of the 38A
allele was significantly higher in case subjects (43.3%),
compared with nonasthmatic control subjects (26.1%),
suggesting an association between this allele and the risk
of asthma. In a previous study, subjects with genotype
38A/A and G/A have been reported to have 6.9- and 4.2-
fold increases, respectively, in risk of asthma (Laing et
al. 1998). In this case, however, no direct relationship
was reported between the G/A polymorphism and what
it may cause, such as decreased activity of transcription
and/or translation. Alternatively, this mutation may be
in linkage disequilibrium with a locus that contributes to
an inherited predisposition for asthma.
In conclusion, our studies demonstrate that UGRP1 is
likely to be a gene candidate in asthma susceptibility and
that the 112A polymorphism may cause a predispo-
sition to asthmatic inflammation by reducing the levels
of UGRP1 in the airway. However, the possibility that
the 112A allele is in linkage disequilibrium with an
allele in a neighboring gene that contributes to inflam-
mation and asthma cannot be excluded. It is likely that
other genes, in addition toUGRP1, contribute to asthma
susceptibility. Furthermore, the possibility cannot be
ruled out that the association of the 112A allele with
asthma may be ethnicity dependent. Additional experi-
ments will be required to demonstrate that UGRP1 ex-
pression is reduced in asthma and to confirm the asso-
ciation of this polymorphism with asthma.
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